Ab-PROTAC Drug Discovery Platform Reduced Off-Target Toxicity Cleavable Linker Conjugation Chemistry
As a leading CRO/CDMO specialized in Targeted Protein Degradation (TPD) and Antibody-Drug Conjugate (ADC) innovation, we deliver fully integrated solutions for PROTAC-Antibody Conjugate (DAC or Ab-PROTAC) development. Our platform merges advanced E3 ligase biology, medicinal chemistry, linker design, and antibody engineering to create precision degraders that combine catalytic protein knockdown with antibody-driven selectivity. From target validation and hit discovery to conjugation process development and preclinical assessment, our team provides a seamless workflow supported by state-of-the-art analytical, bioassay, and CMC capabilities. Partnering with us enables you to accelerate next-generation biotherapeutics that go beyond inhibition-achieving true selective protein degradation with optimized safety and pharmacokinetic profiles.
Traditional PROTAC molecules face challenges such as poor pharmacokinetics, limited tissue selectivity, and systemic toxicity. On the other hand, monoclonal antibodies, though precise, often lack intracellular access. Our PROTAC-Antibody Conjugate (DAC) technology solves these issues by combining the catalytic degradation power of PROTACs with the precise targeting and delivery capabilities of antibodies. Key advantages include:
Improved selectivity: Antibody-mediated delivery ensures degradation occurs only in antigen-positive cells.
Enhanced pharmacokinetics: Larger molecular weight and controlled release improve half-life and bioavailability.
Reduced off-target effects: Payload activation only after internalization minimizes systemic exposure.
Broader therapeutic reach: Enables degradation of previously "undruggable" intracellular proteins.
We provide end-to-end PROTAC-Antibody Conjugate (DAC/Ab-PROTAC) development, integrating chemistry, biology, and analytics into a single, streamlined workflow. Each stage is managed by experienced scientists and project managers to ensure precision, reproducibility, and rapid turnaround.
Feasibility & Design Consulting
Antibody & Linker Engineering
Conjugation Chemistry Development
Analytical & Biophysical Characterization
In Vitro & In Vivo Validation
CMC & Scale-UpOur streamlined workflow integrates scientific rigor, transparent communication, and fast project execution - ensuring that each PROTAC-Antibody Conjugate program progresses efficiently from concept to preclinical validation.
We begin by understanding your biological objectives, therapeutic targets, and desired E3 ligase. Our scientists evaluate project feasibility, identify technical risks, and propose the optimal strategy for antibody selection, linker chemistry, and conjugation design.
Once feasibility is confirmed, we design and prepare custom antibodies and cleavable linkers tailored to your PROTAC structure. Early stability and binding tests ensure compatibility and functionality before conjugation.
We develop and refine conjugation methods to achieve the ideal Drug-to-Antibody Ratio (DAR) and payload homogeneity. Reaction parameters, purification conditions, and analytical quality control are standardized for scale-up readiness.
Each conjugate undergoes extensive biophysical and chemical testing - including LC-MS, SEC-MALS, CE-SDS, and binding affinity assays - to confirm structural integrity, stability, and biological performance.
Our biology team validates degradation efficiency, internalization, and cytotoxicity using cell-based assays and animal models. We deliver detailed reports covering PK/PD profiles and efficacy endpoints.
Our platform uniquely combines targeted protein degradation chemistry with antibody conjugation engineering, enabling us to design payloads and linkers that maintain both degradation potency and antibody selectivity - a rare combination in this emerging field.
From early discovery to IND-enabling studies, we provide modular service packages that adapt to your stage and budget. You can engage us for a single step or the entire DAC development pipeline, ensuring maximum flexibility and cost efficiency.
We employ industry-standard analytical tools - LC-MS, HIC-HPLC, CE-SDS, and bioassay platforms - for accurate DAR measurement, payload homogeneity assessment, and stability verification. This ensures your conjugates meet regulatory expectations and batch consistency.
With optimized workflows and parallel task execution, our turnaround times are significantly shorter than traditional CRO schedules. Fast feasibility evaluation and early-risk mapping help you make go/no-go decisions quickly.
We ensure complete IP protection and transparent communication throughout your project. Our scientists work as an extension of your R&D team, providing data-driven insights and strategic recommendations at every milestone.
Our PROTAC-Antibody Conjugate (DAC / Ab-PROTAC) technology is highly versatile and applicable across multiple research and therapeutic domains. Below are the key areas where this platform brings measurable value and innovation:
While an Antibody-Drug Conjugate (ADC) delivers a cytotoxic payload to kill cells, a Degrader Antibody Conjugate (DAC) delivers a PROTAC payload that triggers targeted protein degradation inside the cell. DACs act catalytically and can eliminate disease-driving proteins without permanently damaging cells.
The technology is in the preclinical to early clinical stage. Several biotech-pharma partnerships (e.g., Nurix-Seagen, Orum-Amgen) are validating its potential. Our service platform enables early-stage feasibility studies and IND-enabling development for clients exploring this frontier.
We typically begin with your target of interest, known antibody or antigen, and any available PROTAC scaffold or E3 ligase preference. If none are defined, our team assists with feasibility analysis, antigen–target matching, and PROTAC design recommendations.
Yes. We can evaluate your existing monoclonal or bispecific antibodies for conjugation compatibility, assess internalization capacity, and design suitable linkers and payload chemistries to create functional DAC candidates.
Our integrated chemistry-biology-CMC capabilities, combined with extensive ADC and TPD expertise, allow us to deliver end-to-end DAC solutions that few CRO/CDMO partners can match. We provide fast feasibility results, robust analytical validation, and IND-ready documentation support.
Partner with us to design and develop PROTAC-Antibody Conjugates (DAC / Ab-PROTACs) that redefine precision medicine. Our integrated chemistry-biology platform, experienced scientific team, and advanced analytical capabilities empower you to move from concept to functional validation with speed and confidence. Contact us today to discuss your target of interest, request a feasibility evaluation, or schedule a confidential consultation with our experts - and take the first step toward creating your next-generation degrader antibody innovation.
